Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Apr 24, 2009

Pfizer Partners with University College London for Stem Cell-Based Therapies

  • Pfizer inked a collaboration and license agreement with University College London (UCL) related to developing stem cell-based therapies for certain ophthalmic conditions. The partnership will examine how human embryonic stem cells differentiate into retinal pigment epithelium (RPE) with the goal of developing treatments primarily for wet and dry age-related macular degeneration.

    While Pfizer’s contributions will be in the form of design and execution of clinical studies, interaction with global regulators, as well as product manufacturing, UCL will focus on research and preclinical studies.

    Pfizer will provide research funding to UCL. The firm will have exclusive, worldwide rights to develop and commercialize an RPE stem cell-based therapeutic in the ophthalmology field. After the completion of preclinical safety studies, Pfizer will have the option to conduct clinical development and commercialization.


    ---

    Recent Pfizer News
    GSK and Pfizer Create HIV-Focused Company (Apr. 16, 2009)
    Pfizer to Increase Stake in Pfizer India with $136.5M Offer (Apr. 13, 2009)
    Pfizer Logs Another Misstep in Late-Stage Development (Apr. 2, 2009)
    MannKind to Buy Pfizer’s Frankfurt Insulin Production Plant for $33M (Mar. 9, 2009)
    Pfizer Gains 39 Generic Therapies from Aurobindo (Mar. 3, 2009)


    Other News in Stem Cell Therapeutics
    Neuralstem's ALS Trial with Stem Cell Therapy Delayed (Feb. 20, 2009)
    VistaGen and Capsant to Develop Stem Cell Technology for Drug R&D (Jan. 15, 2009)
    Pluripotent Stem Cells Created for 10 Diseases (Aug. 7, 2008)
    Gamida Obtains Rights to Amgen Cytokines to Produce Stem Cell Cancer Drug (July 21, 2008)
    Osiris Obtains $2M from JDRF with Clinical Advancement of Stem Cell Therapy (June 25, 2008)



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »